Smith & Nephew

SNN

Market cap $13.8B

For a business built on orthopaedics and wound care, Smith & Nephew PLC (LSE:SN) has given investors a fair bit of whiplash. Its third-quarter update sent the shares down about 10% after organic revenue growth came in weaker than hoped and, crucially, slowed from the second quarter despite earlier guidance that it would accelerate.

Smith & Nephew plc ( SNN ) Q3 2025 Sales Call November 6, 2025 3:30 AM EST Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets, Research Division Veronika Dubajova - Citigroup Inc., Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Graham Doyle - UBS Investment Bank, Research Division Kane Slutzkin - Deutsche Bank AG, Research Division Julien Dormois - Jefferies LLC, Research Division David Adlington - JPMorgan Chase & Co, Research Division Presentation Operator Good morning. Thank you for attending today's Smith & Nephew Quarter 3 2025 Trading Report.

Smith & Nephew PLC (LSE:SN) shares were the worst faller on the FTSE 100 on Thursday morning, down 12% after reporting lower revenues than expected Third-quarter revenue growth came in at 5.0%, below consensus expectations of 6.1%, with orthopaedics slower than forecast due to a weaker performance in US knee replacement surgeries, with sport medicine also softer than expected. UBS analysts said: "while guidance was reiterated, we think this will disappoint versus expectations".

Smith & Nephew plc maintains a 'Hold' rating due to valuation concerns and limited near-term upside despite recent operational improvements. Sequential growth across all business units and a 100 basis point trading margin expansion support management's confidence in achieving full-year guidance. Technical analysis reveals significant resistance at $38 and $40-$42, with bearish intermediate signals suggesting potential price weakness over the next 6-10 months.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery.

Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts organization, have announced a multi-year extension of their landmark worldwide marketing partnership forged in 2024.  Under the renewal, Smith+Nephew will continue as UFC's Preferred Sports Medicine Technology Partner, a designation it received as UFC's inaugural partner in that category, to activate its brand around some of UFC's biggest events.

Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound Journal,1 demonstrating the pressure injury prevention mechanism of action of ALLEVYN COMPLETE CARE Foam Dressing and its ability to absorb and dissipate friction and shear forces.

Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its CORIOGRAPH Pre-Op Planning and Modeling Services for total shoulder arthroplasty, now available in the United States. This innovative software offers image-based planning capabilities that enable surgeons to create a patient-specific plan for shoulder replacement procedures by using enhanced clinical decision-making through advanced biomechanical simulation that accounts for scapulothoracic motion.1-6 The first procedures using CORIOGRAPH Services for Shoulder were recently completed by Dr. Christopher Klifto, Shoulder Surgeon at Duke University.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.